Full-Time

Associate Director

Program and Alliance Management, Discovery to Phase II

Updated on 9/11/2026

Deadline 9/10/27
Monte Rosa Therapeutics

Monte Rosa Therapeutics

201-500 employees

Develops targeted protein degraders for therapy

Compensation Overview

CHF145k - CHF170k/yr

Boston, MA, USA

In Person

Travel is required.

Master's, PhD

Category
Project & Program Management (1)
Required Skills
Microsoft Office
Risk Management

Get referred to Monte Rosa Therapeutics

See people who can refer or advise you

Requirements
  • A Master of Science or Ph.D. in biological sciences or a related field.
  • At least 6 years of biotech or pharmaceutical industry experience, including 3–5 years managing cross-functional projects and alliances from discovery through early clinical development.
  • Strong understanding of research and preclinical drug development.
  • Experience working within a matrix organization and on multidisciplinary drug development teams.
  • Management, organizational, and problem-solving skills to develop and effectively monitor program plans, budgets, and timelines.
  • Ability to identify and resolve problems and conflicts at the appropriate level, including effective escalation.
  • Interpersonal and communication skills, attention to detail, and the ability to work effectively and efficiently.
  • Experience with budgeting, including tracking and forecasting.
  • Detailed knowledge of Microsoft Office, Microsoft Project, Smartsheet, or other project management software tools.
  • Ability to travel.
Responsibilities
  • Lead and coordinate, with project and program leads, the development and delivery of Integrated Development Plans for assigned projects in alignment with corporate goals, ensuring integration with each function.
  • Actively manage and monitor program progress to ensure accountability for timely execution of program activities and milestones.
  • Identify critical path activities and opportunities to optimize program execution without compromising quality or compliance.
  • Proactively identify potential issues or risks and drive resolution or effective mitigation strategies.
  • Monitor issues through resolution and ensure key stakeholders are informed of outcomes and program implications.
  • Direct and ensure communication alignment with internal stakeholders and, as needed, external partners regarding plans, status, deadlines, data requirements, logistics, and other project-related issues.
  • Establish effective relationships with external alliance counterparts and plan and conduct joint meetings as defined by the agreement, ensuring contractual obligations are met and roles, responsibilities, and obligations are understood and followed.
  • Facilitate program and alliance team meetings, including developing agendas and minutes and maintaining action-item logs, detailed integrated timelines, risk registers, and related records.
  • Manage, monitor, track, and communicate cross-functional program timelines, deliverables, risk registers, critical paths, and cross-program dashboards.
  • Communicate proactively across functions and escalate critical issues.
  • Champion programs through the governance process by facilitating decision-making, including scenario plans and risk-benefit analysis, and ensure outcomes and decisions are communicated.
  • Partner with teams and Finance to develop and manage program budgets.
Desired Qualifications
  • Knowledge and experience in the Investigational New Drug preparation process.
Monte Rosa Therapeutics

Monte Rosa Therapeutics

View

Monte Rosa Therapeutics develops molecular glue degraders (MGDs) to eliminate disease-causing proteins rather than inhibit them. Its QuEEN discovery engine combines AI-guided chemistry, proteomics, structural biology, and diverse chemical libraries to design MGDs that recruit target proteins to an E3 ubiquitin ligase, marking them for destruction by the proteasome. The company operates through internal clinical programs and partnerships with larger pharma, such as Roche and Novartis, to fund development and share milestones and royalties. Its goal is to discover, develop, and commercialize MGDs to treat oncology and autoimmune/inflammatory diseases, expanding the range of druggable targets.

Company Size

201-500

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

2018

Get referred to Monte Rosa Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Aug. 24, 2026 MODeFIRe-1 dosing started with J&J-supplied apalutamide, accelerating MRT-2359 execution.
  • Aug. 6, 2026 cash reached $626.0 million, funding operations into 2029.
  • Novartis activated phase 2 MRT-6160 in Sjögren’s disease, triggering up to $2.1 billion milestones.

What critics are saying

  • MODeFIRe-1 phase 2 readouts in 2026 can kill the prostate cancer thesis fast.
  • Jan. 2026 and May 2024 offerings diluted holders and invite more financing before profitability.
  • Novartis controls MRT-6160 development; a partner reprioritization would erase Monte Rosa’s lead asset value.

What makes Monte Rosa Therapeutics unique

  • QuEEN engine keeps producing oral, selective molecular glue degraders from undruggable targets.
  • Novartis licensed MRT-6160 globally in 2024, validating Monte Rosa’s platform externally.
  • Roche and Novartis partnerships fund discovery without forcing Monte Rosa to build a sales force.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
Grafa
Aug 24th, 2026
Monte Rosa starts MRT-2359 prostate trial.

Monte Rosa starts MRT-2359 prostate trial. * Monte Rosa Therapeutics dosed the first patient in a Phase 2 trial of MRT-2359 plus apalutamide for metastatic castration-resistant prostate cancer. * The MODeFIRe-1 study will enroll up to 25 patients with AR mutation-positive mCRPC. * Monte Rosa stated that prior combination data showed PSA responses in 5 of 5 AR-mutant patients in an earlier study. Monte Rosa Therapeutics (NASDAQ:GLUE) announced that the first patient has been dosed in MODeFIRe-1, a Phase 2 trial evaluating investigational molecular glue degrader MRT-2359 with apalutamide in patients with AR mutation-positive metastatic castration-resistant prostate cancer. The trial will enroll up to 25 patients with mCRPC who previously received a second-generation androgen receptor inhibitor and will evaluate treatment responses and safety outcomes. The study will assess PSA responses, RECIST responses, duration of response, radiographic progression-free survival, PSA progression-free survival, and safety, while enrollment in the prior expansion arm with enzalutamide has been completed. Monte Rosa stated that updated data from six AR-mutant patients in the previous expansion arm is expected by year-end. The company previously reported that the enzalutamide combination study showed PSA responses in 5 of 5 AR-mutant patients, a 100% disease control rate, and two RECIST responses among heavily pretreated patients. Monte Rosa Therapeutics develops molecular glue degraders designed to target disease-related proteins, with MRT-2359 being evaluated in cancer indications including AR mutation-positive prostate cancer. Frequently asked questions. GLUE signals

Monte Rosa Therapeutics
Jul 21st, 2026
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering - Monte Rosa Therapeutics

BOSTON, May 16, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the pricing of an underwritten public offering of 10,638,476 shares of its

Yahoo Finance
Mar 22nd, 2026
Monte Rosa and J&J partner on MRT-2359 prostate cancer trial, shares up 169.5% over year

Monte Rosa Therapeutics has announced a supply agreement with Johnson & Johnson to evaluate MRT-2359 combined with ERLEADA in metastatic castration-resistant prostate cancer. The company is initiating a Phase 2 trial testing this combination, whilst retaining control of the study and sponsorship. Additional positive clinical data for MRT-2359 in advanced prostate cancer were presented at ASCO GU 2026. Johnson & Johnson will supply ERLEADA, reducing Monte Rosa's cash requirements for sourcing the combination partner. Monte Rosa reported a full-year 2025 net loss of $38.63 million and remains unprofitable, with no profitability forecast over the next three years. Shareholders experienced substantial dilution over the past year, and an $83.63 million shelf registration indicates potential future equity issuance remains possible.

Yahoo Finance
Mar 18th, 2026
Monte Rosa Therapeutics reports $0.55 Q4 loss, misses revenue estimates by 73%

Monte Rosa Therapeutics reported a fourth-quarter loss of $0.55 per share, missing the Zacks Consensus Estimate of a $0.47 loss, representing a negative earnings surprise of 17.02%. This compares to earnings of $0.23 per share in the prior-year period. The biopharmaceutical company posted revenues of $2.78 million for the quarter ended December 2025, missing consensus estimates by 72.9%. Year-ago revenues totalled $60.65 million. Over the past four quarters, the company has surpassed consensus earnings estimates three times and topped revenue estimates three times. Monte Rosa shares have gained 4.3% year-to-date, outperforming the S&P 500's 2.1% decline. However, unfavourable estimate revision trends have resulted in a Zacks Rank of 4 (Sell), suggesting potential near-term underperformance.

Intellectia AI
Jan 9th, 2026
Monte Rosa Therapeutics prices $11.1M public offering to fund cancer therapy R&D

Monte Rosa Therapeutics has priced an underwritten public offering at $11.1 million to fund future research and operations. The biopharmaceutical company plans to use proceeds for clinical trials and research and development projects, particularly focusing on innovative cancer therapies. The offering aims to strengthen Monte Rosa's financial flexibility and enhance its competitive position in the biopharmaceutical market. Specific share details were not disclosed. The company expects the funding will help it capitalise on opportunities in the rapidly evolving sector.